X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (230) 230
Publication (55) 55
Conference Proceeding (6) 6
Book / eBook (3) 3
Book Chapter (2) 2
Newspaper Article (2) 2
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (147) 147
index medicus (111) 111
hematology (99) 99
male (96) 96
female (93) 93
oncology (89) 89
middle aged (85) 85
aged (78) 78
antineoplastic combined chemotherapy protocols - therapeutic use (76) 76
adult (72) 72
chemotherapy (54) 54
rituximab (53) 53
prognosis (46) 46
non-hodgkins-lymphoma (45) 45
treatment outcome (44) 44
disease-free survival (36) 36
lymphomas (33) 33
adolescent (31) 31
neoplasm staging (30) 30
retrospective studies (30) 30
antineoplastic combined chemotherapy protocols - adverse effects (29) 29
aged, 80 and over (27) 27
cyclophosphamide - administration & dosage (24) 24
cancer (23) 23
survival analysis (23) 23
young adult (23) 23
antineoplastic combined chemotherapy protocols - administration & dosage (21) 21
prednisone - administration & dosage (21) 21
therapy (21) 21
vincristine - administration & dosage (21) 21
disease (20) 20
doxorubicin - administration & dosage (20) 20
elderly-patients (20) 20
hematology, oncology and palliative medicine (20) 20
lymphoma (20) 20
risk factors (20) 20
b-cell lymphoma (19) 19
hemic and lymphatic diseases (19) 19
recurrence (19) 19
survival (19) 19
combined modality therapy (18) 18
cyclophosphamide (18) 18
italy (18) 18
phase-ii (18) 18
antineoplastic agents - therapeutic use (17) 17
lymphoma, large b-cell, diffuse - drug therapy (17) 17
antibodies, monoclonal, murine-derived - administration & dosage (16) 16
hodgkin disease - drug therapy (16) 16
lymphoma, non-hodgkin - drug therapy (16) 16
transplantation (16) 16
lymphoma, follicular - pathology (15) 15
stem-cell transplantation (15) 15
trial (15) 15
abridged index medicus (14) 14
follow-up studies (14) 14
high-dose chemotherapy (14) 14
bone-marrow-transplantation (13) 13
follicular lymphoma (13) 13
lymphoma, follicular - drug therapy (13) 13
patients (13) 13
transplantation, autologous (13) 13
care and treatment (12) 12
remission induction (12) 12
salvage therapy (12) 12
stem cells (12) 12
cyclophosphamide - therapeutic use (11) 11
fdg-pet (11) 11
follow-up (11) 11
hematopoietic stem cell transplantation (11) 11
positron-emission-tomography (11) 11
prospective studies (11) 11
randomized controlled-trial (11) 11
research (11) 11
stem cell transplantation (11) 11
survival rate (11) 11
1st-line treatment (10) 10
aggressive lymphoma (10) 10
bleomycin - administration & dosage (10) 10
clinical trials (10) 10
doxorubicin (10) 10
doxorubicin - therapeutic use (10) 10
fludarabine (10) 10
hodgkin's disease (10) 10
kaplan-meier estimate (10) 10
patient outcomes (10) 10
prednisone - therapeutic use (10) 10
rituximab - administration & dosage (10) 10
vincristine - therapeutic use (10) 10
analysis (9) 9
chronic lymphocytic-leukemia (9) 9
cyclophosphamide - adverse effects (9) 9
diffuse large b-cell lymphoma (9) 9
doxorubicin - adverse effects (9) 9
drug therapy (9) 9
gene-expression (9) 9
hodgkin disease - mortality (9) 9
lymphoma, large b-cell, diffuse - mortality (9) 9
lymphoma, large b-cell, diffuse - pathology (9) 9
lymphoma, non-hodgkin - pathology (9) 9
lymphoma, non-hodgkin - therapy (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 07/2011, Volume 29, Issue 20, pp. 2766 - 2772
Purpose Primary testicular lymphoma (PTL) has poor prognosis with failures in contralateral testis, CNS, and extranodal sites. To prevent these events, we... 
RICOVER-60 | PROGNOSTIC-FACTORS | RESPONSE CRITERIA | ONCOLOGY | MALIGNANT-LYMPHOMA | NON-HODGKINS-LYMPHOMA | CENTRAL-NERVOUS-SYSTEM | RECURRENCE | RANDOMIZED CONTROLLED-TRIAL | CHEMOTHERAPY PLUS RITUXIMAB | ELDERLY-PATIENTS | Doxorubicin - therapeutic use | Recurrence | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Testicular Neoplasms - pathology | Central Nervous System Neoplasms - secondary | Testicular Neoplasms - radiotherapy | Central Nervous System Neoplasms - prevention & control | Drug-Related Side Effects and Adverse Reactions | Adult | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Lymphoma, Large B-Cell, Diffuse - pathology | Rituximab | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - radiotherapy | Methotrexate - adverse effects | Testicular Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Methotrexate - administration & dosage | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Index Medicus
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2014, Volume 89, Issue 2, pp. 370 - 375
Purpose Image-guided intensity modulated radiation therapy (IG-IMRT) allows for margin reduction and highly conformal dose distribution, with consistent... 
Radiology | Hematology, Oncology and Palliative Medicine | ABVD | ONCOLOGY | BREAST-CANCER RISK | NODE RADIOTHERAPY | DISEASE | FIELD RADIOTHERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | CHEMOTHERAPY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hodgkin Disease - pathology | Humans | Middle Aged | Male | Vinblastine - administration & dosage | Radiotherapy, Intensity-Modulated - adverse effects | Young Adult | Hodgkin Disease - radiotherapy | Mediastinal Neoplasms - drug therapy | Aged, 80 and over | Hodgkin Disease - drug therapy | Adult | Female | Retrospective Studies | Radiotherapy, Image-Guided - adverse effects | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Radiotherapy, Intensity-Modulated - methods | Bleomycin - administration & dosage | Tumor Burden | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mediastinal Neoplasms - pathology | Radiotherapy, Image-Guided - methods | Mediastinal Neoplasms - radiotherapy | Adolescent | Radiotherapy, Conformal - adverse effects | Aged | Combined Modality Therapy - methods | Radiotherapy, Conformal - methods | Sects | Lymphomas | Radiotherapy | Nuclear radiation | Index Medicus | PATIENTS | DOXORUBICIN | BLEOMYCIN | VINBLASTINE | RADIATION DOSES | TOXICITY | PLANNING | LYMPHOMAS | RADIATION DOSE DISTRIBUTIONS | MEDIASTINUM | RADIOLOGY AND NUCLEAR MEDICINE | RADIOTHERAPY
Journal Article
The Lancet Oncology, ISSN 1470-2045, 02/2018, Volume 19, Issue 2, pp. 162 - 163
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 7, pp. 730 - 737
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2013, Volume 87, Issue 2, pp. 311 - 316
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2011, Volume 365, Issue 3, pp. 203 - 212
BEACOPP combination chemotherapy was compared with ABVD chemotherapy in advanced Hodgkin's disease. BEACOPP therapy was associated with higher initial rates of... 
CELL TRANSPLANT | MEDICINE, GENERAL & INTERNAL | VINORELBINE | MOPP | DISEASE | REGIMEN | IFOSFAMIDE | CHEMOTHERAPY | STANDARD | HYBRID | FERTILITY | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Lymphomas | Hodgkin's disease
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 07/2016, Volume 95, Issue 4, pp. 1239 - 1243
To validate, in a monoinstitutional cohort with extended follow-up, that post–rituximab chemotherapy (R-CT) F-fluorodeoxyglucose positron emission tomography (... 
Journal Article
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 07/2016, Volume 95, Issue 4, pp. 1239 - 1243
Purpose: To validate, in a monoinstitutional cohort with extended follow-up, that post-rituximab chemotherapy (R-CT) super(18)F-fluorodeoxyglucose positron... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2008, Volume 26, Issue 32, pp. 5156 - 5164
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2016, Volume 34, Issue 12, pp. 1376 - 1385
Journal Article
Mediterranean Journal of Hematology and Infectious Diseases, ISSN 2035-3006, 12/2016, Volume 9, Issue 1, p. e2017009
Journal Article
Journal Article